The trend for increased vaccine production is being driven by the requirement to produce affordable prophylactic vaccines for use in emerging markets, and also for newer types of therapeutic vaccines to treat an ever-increasing array of diseases such as cancer. These drivers, coupled with the current need to produce vaccines rapidly for pandemic threats and seasonal influenza prevention, has lead to the investigation of rapid method development for optimising the scale-up of cGMP-compliant manufacturing processes…
JUST PUBLISHED: "Standardized and GMP-Ready, Closed-System Processing of Expanded Adipose-Derived Stem Cells Using the Gibco CTS
Rotea System Across 2D and 3D Bioreactor Expansions." Click on the OPEN ACCESS ARTICLES tab below.
